Cyclodextrin News

May 7, 2026 CD as API / Pharma applications / Uncategorized

Sugammadex vs Neostigmine: Effects on Obese Patients’ Recovery

Compared with neostigmine, sugammadex promotes faster neuromuscular recovery, but its impact on diaphragmatic function and respiratory recovery in the morbidly

close up photography of adult black and white short coat dog

March 25, 2026 CD derivatives / Drug delivery / Pharma applications

Cantrixil: Advancing a Molecule’s Career with a Cyclodextrin Carrier

The success story of Cantrixil, a potent anti-cancer drug candidate, has been followed on our blog for years, and now

March 24, 2026 Drug delivery / Pharma applications

Oculis: eye drops with Dexamethasone/gamma-CD complex Phase 3 study concluded soon

Oculis’s most advanced product candidate, OCS-01, is currently in Phase 3 development and aims to be the first eye drop

January 19, 2026 CD as API / Pharma applications

Sugammadex vs. Neostigmine Reversal After Thoracoscopic Thymectomy in Myasthenia Gravis

Rapid and complete reversal of residual neuromuscular blockade (rNMB) is essential for safe postoperative recovery in patients with myasthenia gravis

September 22, 2025 CD as API / Pharma applications

7 of 9 patients showed stabilization or improvement: preliminary data from ongoing Phase 3 TransportNPC™ clinical trial

Rafael Holdings, Inc. announced that data from Cyclo Therapeutics’ Phase 3 TransportNPC™ open-label, single-arm sub-study evaluating Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) for Niemann-Pick

September 16, 2025 CD as API / Drug delivery / Pharma applications

Cyclodextrin-based therapeutics delivery systems: A review of current clinical trials

Cyclodextrins (CDs) and their polymers are gaining momentum as advanced drug delivery systems. A recent review (https://www.sciencedirect.com/science/article/pii/S2590257125000203) highlights their progress